Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA sets generic facility user fees; warns pay up or no US entry

This article was originally published in Scrip

Executive Summary

The US FDA on 16 January rolled out the industry user fee rates for fiscal year 2013 for facilities where generic finished dosage form (FDF) medicines and active pharmaceutical ingredients (APIs) are made – with regulators warning that companies that fail to pay up could have their applications snubbed and their products deemed misbranded and denied entry into the US.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts